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Detection of onconeural antibodies is important because establishes a definitive
diagnosis of paraneoplastic neurological syndrome (PNS). The recommended method
for diagnosis of onconeural antibodies is by immunohistochemistry on rodent brain
sections and confirmation of results by immunoblot. However, in many diagnostic
laboratories samples are only tested with commercial line blots. In this study we
inquired whether this change in diagnostic methodology (line blot alone vs. combined
immunohistochemistry and line blot) would affect the results. Among 439 samples
examined by immunohistochemistry and a commercial line blot (Euroimmun, Lübeck,
Germany) 96 (22%) were positive by line blot, and their clinical information was
reviewed. Onconeural antibodies were detected by both assays in 46/96 (48%) patients
(concordant group) whereas 50 (52%) were only positive by line blot (discordant group).
In the concordant group 42/46 (91%) patients had a definite diagnosis of PNS whereas
in the discordant group only 4/50 (8%) had PNS (p < 0.00001). None of the 14 patients
with ZIC4 antibodies and 1/13 (8%) with Yo antibodies demonstrated only by line blot had
PNS. These findings show a robust diagnostic value of combined diagnostic techniques,
and both should be used to demonstrate onconeural antibodies, If antibody testing is
performed only with line blot assay, positive bands should be confirmed by rodent brain
immunohistochemistry. For ZIC4 or Yo antibody testing, line blot positivity with negative
immunohistochemistry has no diagnostic significance, and for the rest of onconeural
antibodies the predictive diagnostic value is low.
Keywords: autoantibodies, paraneoplastic neurological syndromes, line blot, onconeural antibodies, diagnostic
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INTRODUCTION
Paraneoplastic neurological syndromes (PNS) include a group of neurological disorders in which
an immune response against an underlying systemic tumor is misdirected to the nervous system
causing the clinical manifestations (1). Most PNS associate with onconeural antibodies against
intracellular antigens (2). Since their initial description it was acknowledged that onconeural
antibodies could occur in 5–15% of patients without cancer or in cancer patients without PNS (2).
Despite these limitations the detection of onconeural antibodies is important because (1) establishes
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a definitive diagnosis of PNS, (2) assists in the differential
diagnosis of atypical clinical syndromes, and (3) directs the search
of potentially involved tumors (2).
Initial studies on onconeural antibodies showed high
specificity for distinct syndromes and tumors. These studies
recommended onconeural antibody testing with rat brain
immunohistochemistry and confirmation of results by
immunoblot (2). However, when testing for onconeural
antibodies became widely available several retrospective studies
showed that the diagnostic value of these antibodies was lower
than expected, resulting in a substantial number of false positive
and negative results that clearly affect patient care (3–7). There
are two potential reasons for this problem; one is related to the
type of disease (rare) and the size of population investigated
(larger than needed). It is known that the lower the prevalence
of a disease, the higher frequency of false results, particularly if a
test is done indiscriminately without solid clinical reasoning (8).
Careful clinical selection of patients that need to be tested for
onconeural antibodies is the best approach to circumvent this
limitation (5, 7). The second reason is likely related to the type
and extent of techniques used to demonstrate the onconeural
antibodies. Commercialization of diagnostic tests has favored
automated testing of multiple antibodies simultaneously (e.g.,
line blot) and may perceive additional studies such as brain
immunohistochemistry, as redundant, time consuming, and
cost increasing. Here we postulated that this limited testing
approach greatly contributes to false positive results. For this
we assessed the frequency of PNS in patients with onconeural
antibodies only demonstrated by line blot and compared it
with the frequency of PNS in patients in whom the onconeural




We reviewed the serum results from 2,437 patients that
were routinely screened for the presence of onconeural
antibodies between October 2016 and August 2019 by
indirect immunohistochemistry on rat cerebellar tissue,
and selected 439 (18%) that were also tested by a commercial
line blot assay (Euroimmun, Lübeck, Germany). In these
439 patients the line blot was used for the following reasons:
(1) confirm immunohistochemical studies suggesting the
presence of an onconeural antibody, (2) specific request of
the referring physician, or (3) confirm results from other
laboratories, particularly when those results did not match with
patients’ symptoms.
Clinical data were collected from patients with positive line
blot assay including the following onconeural antibodies: Hu
(ANNA1), Yo (PCA1), CV2 (CRMP5), Ri (ANNA2), Ma2, Tr
(DNER), Zic-4, SOX1, and amphyphisin. Patients with positive
bands for GAD65, titin, and recoverin antibodies included
also in the same kit were excluded from the analysis. Clinical
information not available in our files was obtained by phone
interview with the referring physicians.
Patients were defined as definite PNS if they had: (1) a
neurological syndrome of unexplained cause associated with
cancer and presence of an onconeural antibody by line blot,
or (2) a classical PNS syndrome (2) (for example sensory
neuronopathy or limbic encephalitis) associated with cancer
or an onconeural antibody. Patients with isolated neurological
symptoms of unclear etiology (for example diplopia, dizziness,
or cramps), or with neurological syndromes with an alternative
diagnosis (for example alcoholic polyneuropathy) were not
considered to have PNS regardless of the presence of cancer or
onconeural antibodies.
The study was approved by the ethics committee of the
Hospital Clínic. Patient information was anonymized prior to
analysis. Written inform consent was not required as the study
was observational and the onconeural antibodies were requested
as part of the routine diagnostic work-up.
Rat Cerebellar Immunohystochemistry
Immunohistochemistry was performed as previously described
(9). Briefly, adult male Wistar rats were anesthetize and perfused
with 0.9% saline solution followed by 2% paraformaldehyde. The
cerebellum was further fixed with 2% paraformaldehyde for 4 h
and cryoprotected with 20% sucrose in phosphate buffered saline
(PBS) overnight. The samples were frozen in methylpropane
chilled in liquid nitrogen. Frozen section were air-dried for
30min and sequentially incubated with 10% normal goat serum
for 20min, patient’s serum (diluted 1:500) for 3 h at 37◦C,
biotinylated goat anti-human IgG for 30min, and the avidin—
biotin immunoperoxidase complex (Vector Labs, Burlingame,
CA, USA) for 30min. The reaction was developed with 0.05%
diaminobenzidine (Sigma, St. Louis, MO, USA) with 0.01%
hydrogen peroxide in PBS with 0.5% Triton X-100.
Line Blot
Serum samples were tested by the commercial immunoblot kit
EUROLINE Paraneoplastic Neurological Syndromes 12 Ag (DL
1111-1601-7G; Euroimmun, Lübeck, Germany) following the
manufacturers’ instructions at serum dilution 1/100. Test strips
were scanned and evaluated for band intensity of Hu (ANNA1),
Yo (PCA1), CV2 (CRMP5), Ri (ANNA2), Ma2, Tr (DNER), Zic-
4, SOX1, and amphiphysin using the EUROLineScan software
(Euroimmun Lübeck, Germany). Following the manufacturer’s
recommendations, onconeural antibody band intensity values
≤10 were considered as negative. Intensity values between 11 and
25 were considered low positive, between 26 and 50 positive, and
>50 strong positive.
RESULTS
Ninety-six out of 439 (22%) patients tested by line blot showed a
reactive band suggesting one or more of the indicated onconeural
antibodies. In total, 118 bands were identified in the 96 sera,
78/96 (81%) sera had one band, and 18/96 (19%) had two
or more bands. In 46 (48%) of 96 patients, the positive line
blot result was concordant with the immunohistochemistry
findings, and in the other 50 (52%) the result was discordant
(negative immunohistochemistry).
Patients with concordant results were more likely to have
PNS than those with discordant results (42/46 [91%] vs. 4/50
[8%]; p < 0.00001; Figure 1A). In the concordant group 42/46
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FIGURE 1 | Associations of diagnosis of paraneoplastic neurological syndrome (PNS) (A) and band intensity in the line blot (B) with samples with onconeural
antibodies detected by line blot and immunohistochemistry assays (concordant) or only by line blot (discordant). Chi-square test used to show statistical significant
differences.
(91%) had a definite diagnosis of PNS and 37 (90%) of them
had cancer. The neurological diagnosis of the remaining four
patients, two had myasthenia, thymoma, and CV2 (CRMP5)
antibodies, and two had brain metastasis in the setting of
lung cancer and SOX1 and Ma2 antibodies (Table 1). In these
four patients the onconeural antibody reflected the presence
of the underlying cancer but they were not related with the
neurological syndrome.
In the discordant group, only 4/50 (8%) patients had a
definite diagnosis of PNS. All had lung cancer (small cell lung
cancer [SCLC] in three), three with paraneoplastic cerebellar
degeneration (PCD) and SOX1, CV2 (CRMP5) and Yo (PCA1)
antibodies, and 1 with Lambert Eaton myasthenic syndrome
and SOX1 antibodies. The neurological diagnoses of the other
46 patients of the discordant group are summarized in Table 1.
Most, 16/46 (35%) had isolated symptoms (cramps, diplopia)
or disorders unrelated with cancer (subarachnoid hemorrhage,
spinal arteriovenous fistula).
Patients with concordant results had a higher frequency of
cancer than those discordant (42/46 [91%] vs. 15/50 [30%], p <
0.00001; Table 1). In the discordant group, 11/15 (73%) patients
with cancer had no PNS, and in nine of them the antibody
suggested by the line blot assay did not match with the tumor
type (Table 2).
The intensity of the 118 positive bands identified in the
line blot assay was analyzed and compared with the results
of the immunohistochemistry and the PNS association.
Forty (34%) of 118 bands had strong intensity and 37
(93%) of the corresponding samples showed positive
immunohistochemistry. In contrast, 28 (24%) bands were
defined as positive, and 50 (42%) as low positive, and the
corresponding samples showed positive immunohistochemistry
in 11/28 (39%) and 14/50 (28%), respectively (p < 0.00001;
Figure 1B). Concerning the association with PNS, strong
intensity bands occurred in samples of 33/45 (73%)
patients with PNS and in 5/51 (10%) patients without
PNS (p < 0.00001).
We then analyzed the specificity of the individual onconeural
antibodies found in the line blot assay for the diagnosis of PNS
(Table 3). For 18 (19%) of the 96 samples with more than one
band, only the more intense band was considered in the analysis.
None of the 14 samples with isolated or predominant ZIC4 bands
(band intensity: low positive nine, positive five, strong positive
zero) was confirmed by immunohistochemistry, and none of the
patients had PNS. Similarly, among 13 patients with discordant
anti-Yo results (all line blot positive, immunohistochemistry
negative) 12 (92%) did not have PNS (band intensity: low positive
seven, positive six, strong positive zero). In contrast, all four
patients with concordant Yo-antibody results had PNS (PCD
female with breast or ovarian cancer) and the band intensity
was strong positive in three and positive in one. For the other
antibodies, the frequency of PNS was 50% (9/18) for CV2
(CRMP5), 53% (8/15) for SOX1, 87% (13/15) for Hu (ANNA1),
and 59% (10/17) for the remaining [Tr, Ri (ANNA2), and
amphiphysin] antibodies detected by line blot assay regardless of
the immunohistochemistry result (Table 3).
DISCUSSION
Our study shows that the type of approach to onconeural
antibody testing using line blot, immunohistochemistry,
or both techniques (dual approach) strongly influences the
accuracy in diagnosing PNS. Indeed, 91% of patients with
onconeural antibodies demonstrated by line blot and rat
immunohistochemistry had PNS compared to 8% of those with
antibodies detected only by line blot. These findings are in line
with a recent report showing that only 33% of onconeuronal
positive cases by commercial line blots had antibodies detectable
with additional techniques (rodent brain immunostaining, or
in-house immunoblot) (10). Moreover, 84% of patients only
positive by line blot had alternative neurologic diagnoses (e.g.,
the final diagnosis was not PNS), whereas most patients with
dual testing positivity had PNS (10).
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TABLE 1 | Neurological syndrome and tumor type in patients with onconeural
antibodies detected by immunohistochemistry and line blot assays (concordant






Median age in years (range) 62 (25–84) 58 (19–84) n.s.
Male/Female 24/22 27/20 n.s.
Definite paraneoplastic syndrome 42 4 <0.00001




Limbic encephalitis 8 0
Paraneoplastic encephalomyelitis 4 0
Brainstem encephalitis 3 0
Lambert Eaton myasthenic syndrome 2 1
Chorea 2 0
Othera 3 0




Brain metastasis 2 1
Psychiatric 0 2
Metabolic encephalopathy 0 2
Neurotoxicity of ICI 0 3
Other 0 16
Cancer 42 15 <0.00001






Hodgkin lymphoma 1 0
Other 2 5
ICI, immune checkpoint inhibitors; n.s., not significant.
a Intestinal pseudo-obstruction; stiff-person syndrome; epilepsia partialis continua.
bMyasthenia and thymoma.
cPolyneuropathy associated with MAG antibodies and Sjögren syndrome, gluten ataxia,
myasthenia, stiff-person syndrome, Morvan syndrome.
In our study, the two antibodies that caused more
misdiagnoses were ZIC4 and Yo. Indeed, none of the 14
samples with isolated or predominant positive ZIC4 bands in the
line blot was confirmed by immunohistochemistry and none of
the patients had PNS. ZIC4 antibodies were initially described
in patients with SCLC without PNS and later in a patient with
subacute cerebellar ataxia without cancer (11, 12). A subsequent
study using an in-house immunoblot with recombinant ZIC4
protein showed that 49 patients with ZIC4 antibodies had
PNS related to lung cancer (40 had additional Hu or CV2
antibodies); 11 additional patients with ZIC4 antibodies had
SCLC without PNS, but none of 175 patients with non-cancer
related neurological disorders or healthy participants had these
antibodies (13). Anti-ZIC4 positive samples were not examined
by immunohistochemistry to know the concordance between
assays. Although the study suggested a tight association between
ZIC4 antibodies and PNS or SCLC, the current study using
the commercial version of the assay did not reproduce that
association; the reasons for this disparity of results are unclear.
As far as Yo-antibody testing is concerned, a potential
reason for false positive results is that the line blot uses the
paraneoplastic cerebellar degeneration related antigen (CDR)
2 to probe for Yo (PCA1) antibodies (14). CDR2 was once
considered the main target antigen of Yo antibodies, but
recent studies showed that the main antigen is CDR2L, which
has 45% sequence homology with CDR2 (15, 16). In rat
brain immunohistochemistry, Yo (PCA1) antibodies react with
CDR2L but not with CDR2 (15). Line blots can detect Yo
(PCA1) antibodies because CDR2 and CDR2L share epitopes
but additionally detects other antibodies (CDR2-restricted) that
do not have PNS-specificity; hence the high frequency of false
positive results.
The line blot assay fared better for other antibodies; 44% of
patients whose samples were positive for CV2, and 87% of those
positive for Hu had PNS. Samples with intense reactive bands
in line blot were more likely to be from patients with PNS and
also to associate with positive immunohistochemistry, compared
with samples with weaker reactive bands. The reason for this
TABLE 2 | Neurological syndrome, tumor and antibody type in 11 patients with cancer, onconeural antibodies detected only by line blot, and no PNS.
Patient Neurological syndrome Tumor Antibody Expected result according to
cancer type?
1 Alcoholic neuropathy NSCLC CV2 (CRMP5) Yes
2 Brain metastasis NSCLC Yo (PCA1) No
3 Neurotoxicity ICI NSCLC Yo (PCA1) No
4 Subarachnoid hemorrhage Ovary Zic4 No
5 Decreased visual acuity Ovary Zic4 No
6 Myasthenia Thymoma CV2 (CRMP5) Yes
7 Morvan syndrome Thymoma Yo (PCA1) No
8 Seizures Rectum Yo (PCA1) No
9 Neuroxicity ICI Prostate SOX1 No
10 Neuroxicity ICI Melanoma CV2 (CRMP5) No
11 Decreased visual acuity CUO Zic4 No
CUO, carcinoma of unknown origin; ICI, immune checkpoint inhibitors.
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TABLE 3 | PNS diagnosis frequency according to antibody type and concordance
between line blot and immunohistochemistry assays.









Zic 4 (14) 0 (0) 0 (0) 0 (0) 14 (100)
Sox1 (15) 6 (40) 2 (13) 1 (7)a 6 (40)
Hu (15) 13 (86) 1 (7)b 0 (0) 1 (7)
CV2 (18) 8 (44) 1 (6) 2 (11)c 7 (39)d
Yo (17) 4 (23) 1 (6)e 0 (0) 12 (71)
Other (17)* 10 (59) 0 (0) 2 (12) 5 (29)
*Ma2, Tr, Ri, amphiphysin results were pooled due to the low number of positive
cases (<10). PNS: paraneoplastic neurological syndrome. Concordant: line blot and
immunohistochemistry assays show the same result.
aSample from a patient with lung cancer and brain metastasis.
bThe sample also had CV2 antibodies concordant with the immunohistochemistry.
cThe two samples were from patients with thymoma and myasthenia.
dAll samples had a low positive intensity in the line blot.
eAtypical for Yo antibodies: PCD male with lung cancer.
finding is that line blots are more sensitive to detect low levels
of onconeural antibodies than immunohistochemistry, but there
are also less specific for PNS. Indeed, low onconeural antibody
levels may occur in patients with cancer without PNS, or in a
small proportion of healthy controls (17, 18).
A limitation of our study is that we did not systematically
test all samples received by line blot and a selection bias could
have been introduced in the analysis. The reason for this, is
that for many years we have found a good association between
onconeural antibodies detected by immunohistochemistry (and
confirmed by immunoblot) with PNS. Based on this experience,
immunohistochemistry has a leading role in our onconeural
antibody testing. However, according to the present results the
testing of all samples by line blot would have increase the number
of patients with positive onconeural antibodies only detected in
the line blot assay and decreased even further the association
with PNS. Another limitation is that the low frequency of some
antibodies such as Tr (DNER), Ri (ANNA2), and amphiphysin,
has prevented to assess the diagnostic value of line blots for each
individual specificity.
These limitations, however, do not affect the main findings
and implications of our study: Patients suspected to have a
PNS related to classical onconeural antibodies should have
dual testing with immunohistochemistry and line blot assays.
If antibody testing is performed only with line blot assay,
positive results must be confirmed by immunohistochemistry.
ZIC4 or Yo antibodies only detected with line blot, most
likely represent false positive results. As for the rest of
antibodies, strong positive intensity bands associate with
a positive immunohistochemistry and PNS diagnosis.
Positive and low positive intensity bands not confirmed by
immunohistochemistry show a low predictive value for PNS
diagnosis. Overall, the implications are important because
PNS usually preceded the diagnosis of cancer and often
have a poor prognosis. Thus, false positive results may lead
to unnecessary tests (cancer screening), increased anxiety
of patients and families, and inappropriate treatment and
prognostic decisions.
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